Boston Scientific Corporation (NYSE:BSX) EVP Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock in a transaction on Monday, October 30th. The stock was sold at an average price of $28.42, for a total value of $440,510.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael P. Phalen also recently made the following trade(s):

  • On Friday, September 29th, Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock. The stock was sold at an average price of $28.72, for a total value of $445,160.00.
  • On Tuesday, August 29th, Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock. The stock was sold at an average price of $26.87, for a total value of $416,485.00.

Boston Scientific Corporation (NYSE:BSX) traded down 1.19% during trading on Monday, reaching $28.16. The company’s stock had a trading volume of 6,885,770 shares. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.93. The company’s 50-day moving average is $29.14 and its 200-day moving average is $27.51. The company has a market capitalization of $38.64 billion, a P/E ratio of 50.38 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.31. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the firm earned $0.27 earnings per share. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. Equities analysts anticipate that Boston Scientific Corporation will post $1.25 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/30/insider-selling-boston-scientific-corporation-bsx-evp-sells-15500-shares-of-stock.html.

Hedge funds have recently bought and sold shares of the company. Swiss National Bank grew its stake in shares of Boston Scientific Corporation by 2.9% in the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock valued at $154,814,000 after buying an additional 156,800 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Boston Scientific Corporation by 10.5% in the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock valued at $253,854,000 after buying an additional 867,983 shares in the last quarter. Sit Investment Associates Inc. grew its stake in shares of Boston Scientific Corporation by 37.8% in the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock valued at $4,134,000 after buying an additional 38,855 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Boston Scientific Corporation by 35,016.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock valued at $84,337,000 after buying an additional 3,033,800 shares in the last quarter. Finally, LS Investment Advisors LLC grew its stake in shares of Boston Scientific Corporation by 5.8% in the third quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock valued at $1,185,000 after buying an additional 2,209 shares in the last quarter. Institutional investors and hedge funds own 90.47% of the company’s stock.

BSX has been the topic of several analyst reports. BidaskClub lowered Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Zacks Investment Research lowered Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Royal Bank Of Canada reiterated a “buy” rating and set a $31.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. Cowen and Company reiterated an “outperform” rating and set a $31.00 price target on shares of Boston Scientific Corporation in a report on Monday, July 17th. Finally, Oppenheimer Holdings Inc. set a $29.00 price target on Boston Scientific Corporation and gave the stock a “hold” rating in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Boston Scientific Corporation presently has an average rating of “Buy” and an average target price of $30.77.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.